NBI-961

Overview

NBI-961 is a NEK2 catalytic inhibitor with human NEK2 IC 50 ~12-fold lower than FLT3 . NBI-961 induces proteasomal degradation of NEK2 . NBI-961 induces G2/ mitosis arrest, apoptosis , and compromises viability in DLBCL cells and patient-derived cells. NBI-961 sensitizes DLBCL cells to doxorubicin and vincristine, and suppresses DLBCL tumor growth in mice. NBI-961 can be used for the research of diffuse large b cell lymphoma.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > NEKs | Products > Signaling Pathways > Mitosis | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-156437
• CAS No.: 2225902-98-5
• Molecular Formula: C28H27F3N6O2S
• Molecular Weight: 568.61
• Purity: 99.73%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
• Availability: In-stock

Source

Original product source